Current pharmacologic options for patients with Alzheimer's disease

Annals of General Hospital Psychiatry

Volumn 2, Issue , 2003, Pages

  Reichman, William E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Cognition; Dementia

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ATYPICAL ANTIPSYCHOTIC AGENT; BETA SECRETASE INHIBITOR; CELECOXIB; CITALOPRAM; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; IBUPROFEN; INDOMETACIN; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROFECOXIB; SELEGILINE; SEROTONIN AGONIST; SERTRALINE; SULINDAC; TACRINE; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC ERROR; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HUMAN; INFLAMMATION; INSOMNIA; LIVER TOXICITY; MEDICAL LITERATURE; MUSCLE CRAMP; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; PATIENT CARE; PERFORMANCE; PUBLIC HEALTH; RESTLESSNESS; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES; VERTIGO; WEIGHT REDUCTION;

EID: 3042609763     PISSN: 14752832     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2832-2-1     Document Type: Review

References (80)

1. Evans DA Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990, 68:267-289
2. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA and Tune LE Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997, 278:1363-1371
3. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H and Hofman A Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 2000, 54:S10-S15
4. Decision Resources March 2000
5. NDTI (Diagnosis codes: 3310, 2900, 2901, 2902, 2903, 2904, 3109, 2912), Moving Annual Total (MAT) March 2001
6. Mayeux R and Sano M Treatment of Alzheimer's disease. N Engl J Med 1999, 341:1670-1679
7. Mohs RC and Ferris SH Measuring response to treatment in Alzheimer's disease: what constitutes meaningful change? Int J Geriatric Psychopharmacol 1998, 1(suppl 1):S7-S14
8. Horsburgh K, McCarron MO, White F and Nicoll JA The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000, 21:245-255
9. Selkoe DJ The origins of Alzheimer disease: A is for amyloid. JAMA 2000, 283:1615-1617
10. Spillantini MG and Goedert M Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998, 21:428-433
11. Cummings JL Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000, 157:4-15
12. Bartus RT, Dean RL, Beer B and Lippa AS The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-417
13. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT and Delon MR Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215:1237-1239
14. Nordberg A and Svensson AL Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998, 19:465-480
15. Rosen WG, Mohs RC and Davis KL A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141:1356-1364
16. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ and Hoover TM A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992, 327:1253-1259
17. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH and Dolan-Ureno J A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992, 268:2523-2529
18. Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, Tesfaye Y, Saint-Martin M, Bacher Y and Carrier L Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990, 322:1272-1276
19. NDTI (Diagnosis codes: 3310, 2900, 2901, 2902, 2903, 2904, 3109, 2912), Moving Annual Total (MAT) July 2001
20. Birks JS, Melzer D and Beppu H Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev 2000, CD001190
21. Rogers SL, Doody RS, Mohs RC and Friedhoff LT Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998, 158:1021-1031
22. Rogers SL, Farlow MR, Doody RS, Mohs R and Friedhoff LT A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998, 50:136-145
23. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL and Friedhoff LT The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999, 10:237-244
24. McLendon BM and Doraiswamy PM Defining meaningful change in Alzheimer's disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999, 12:39-48
25. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG and Ferris SH Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(suppl 2):S22-S32
26. Rogers SL, Doody RS, Pratt RD and Ieni JR Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000, 10:195-203
27. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA and Pratt RD A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001, 57:481-488
28. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A and Subbiah P A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001, 57:489-495
29. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E and Massman P Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001, 12:295-300
30. Goldblum MC, Tzortzis C, Michot JL, Panisset M and Boller F Language impairment and rate of cognitive decline in Alzheimer's disease. Dementia 1994, 5:334-338
31. Fillit HM, Gutterman EM and Brooks RL Impact of donepezil on caregiving burden for patients with Alzheimer's disease. Int Psychogeriatr 2000, 12:389-401
32. Freeman SE and Dawson RM Tacrine: a pharmacologic review. Prog Neurobiol 1991, 36:257-277
33. Corey-Bloom J, Anand R and Veach J A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinestease inhibitor, in patients with mild to moderately severe Alzheimer's disease for the ENA 713 B352 Study Group. Int J Geriatric Psychopharmacol 1998, 1:55-65
34. Birks J, Grimley J Evans, Iakovidou V and Tsolaki M Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000, CD001191
35. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R and Gharabawi M Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999, 318:633-638
36. Farlow M, Anand R, Messina J, Hartman R and Veach J A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000, 44:236-241
37. Maelicke A and Albuquerque EX Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000, 393:165-170
38. Levin ED and Simon BB Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998, 138:217-230
39. Levin ED and Rezvani AH Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000, 393:141-146
40. Woodruff-Pak DS, Vogel RW and Wenk GL Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A 2001, 98:2089-2094
41. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX and Maelicke A Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl 2000, 176:68-73
42. Mintzer JE, Yuan W and Kershaw P Efficacy of galantamine in patients with Alzheimer's disease (AD) with previous exposure to cholinesterase inhibitors. Poster presented at: American College of Neuropsychopharmacology, San Juan, Puerto Rico December 10-14 2000
43. Tariot P and Winblad B Galantamine, a novel treatment for Alzheimer's disease: a review of the long-term benefits to patients and caregivers. In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (Edited by: Iqbal K, Sisodia SS, Winblad B) John Wiley & Sons, Ltd 2001, 707-723
44. Rockwood K, Mintzer J, Truyen L, Wessel T and Wilkinson D Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001, 71:589-595
45. Wilcock GK, Lilienfeld S and Gaens E Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000, 321:1445-1449
46. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S and Ding C A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000, 54:2269-2276
47. Stahl S, Markowitz J and Gutterman E Aricept® (donepezil) is associated with increased hypnotic use among Alzheimer's disease patients living in the community. Poster presented at: International Psychogeriatric Association 2001, 9-14
48. Blesa R Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000, 11(suppl 1):28-34
49. Rockwood K and Kershaw P Galantamine's clinical benefits are not offset by sleep disturbance: a 3-month placebo-controlled study in patients with Alzheimer's disease. Poster presented at: World Alzheimer Congress, Washington, DC July 9-18 2000
50. Robillard A, McKelvey R and Nasreddine Z Galantamine improves quality of sleep in patients previously treated with donepezil (preliminary results). Poster presented at: American Association for Geriatric Psychiatry, San Francisco, California February 23-26 2001
51. Raskind MA, Peskind ER, Wessel T and Yuan W Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000, 54:2261-2268
52. Raskind M and Truyen L The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Poster presented at: American Association for Geriatric Psychiatry, Orlando, Florida February 24-27 2002
53. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M and Ferris S An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(suppl 2):S33-S39
54. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA and Gornbein J The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314
55. Wilcock G and Lilienfeld S Galantamine alleviates caregiver burden in Alzheimer's disease: a 6-month placebo-controlled study. Poster presented at: World Alzheimer Congress, Washington, DC July 9-18 2000
56. Farlow MR Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clin Ther 2001, 23(suppl A):A13-A24
57. Anand R, Shua-Haim J and Harman R Counterintuitive effects of a treatment washout in Alzheimer's disease patients switched from donepezil to rivastigmine. Poster presented at: American Neurological Association, Boston, Massachusetts October 15-18 2000
58. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS and Thal LJ A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997, 336:1216-1222
59. Sultzer DL Depression, delusions, and agitation in Alzheimer's disease. Postgraduate Medicine - A Special Report - Practical Alzheimer's Disease Management 1999, 19-26
60. Mega MS, Cummings JL, Fiorello T and Gornbein J The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996, 46:130-135
61. Hinchcliffe AC, Hyman IL, Blizard B and Livingston G Behavioural complications of dementia - can they be treated? Int J Geriatr Psychiatry 1995, 10:839-847
62. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J and Brecher M Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999, 60:107-115
63. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD and Breier A Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000, 57:968-976
64. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ and Irvine C Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001, 9:58-66
65. Cummings JL and Back C The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998, 6:S64-S78
66. Tariot P, Gaile SE, Castelli NA and Porsteinsson AP Treatment of agitation in dementia. New Dir Ment Health Serv 1997, 9:109-123
67. Lilienfeld S Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev 2002, 8:159-176
68. Rosler M The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002, 20-36
69. Wilkinson DG, Hock C, Farlow M, Van Baelen B and Schwalen S Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months. Int J Clin Pract 2002, 56:509-514
70. Guela C and Mesulam M-M Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Alzheimer Disease (Edited by: Terry RD, Katzman R, Bick KL) New York, Raven Press 1994, 263-291
71. Rezvani AH and Levin ED Cognitive effects of nicotine. Biol Psychiatry 2001, 49:258-267
72. Arneric SP Neurobiology and clinical pathophysiology of neuronal nicotinic acetylcholine receptors. In: Nicotine in Psychiatry, Psychopathology and Emerging Therapeutics Washington, D.C., American Psychiatric Press, Inc 2000, 3-35
73. Zajaczkowski W, Frankiewicz T, Parsons CG and Danysz W Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 1997, 36:961-971
74. Misztal M, Frankiewicz T, Parsons CG and Danysz W Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine. Eur J Pharmacol 1996, 296:1-8
75. Reisberg B, Windscheif U, Ferris SH, Hingorani VN, Stoefler A and Moebius H-J Memantine in moderately severe to severe Alzheimer's disease (AD): results of a placebo-controlled 6-month trial Neurobiol Aging 2000, 21(suppl 1):S275
76. Winblad B and Poritis N Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999, 14:135-146
77. Ruther E, Glaser A, Bleich S, Degner D and Wiltfang J A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000, 33:103-108
78. Jain KK Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000, 9:1397-1406
79. Schenk DB, Seubert P, Lieberburg I and Wallace J Beta-peptide immunization: a possible new treatment for Alzheimer disease. Arch Neurol 2000, 57:934-936
80. Dovey HF, John V, Anderson JP, Chen LZ, de Saint A, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Ni B, Nissen JS, Porter WJ, Potts BD, Reel JK, Stephenson D, Su Y, Shipley LA, Whitesitt CA, Yin T and Audia JE Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001, 76:173-181